News | July 22, 2021
Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Sun Pharma has committed Rs. 100 crores towards these initiatives
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
Subscribe To Our Newsletter & Stay Updated
